

# Resource Summary Report

Generated by [RRID](#) on Aug 5, 2026

## Damon Runyon Cancer Research Foundation

RRID:SCR\_005106

Type: Tool

---

### Proper Citation

Damon Runyon Cancer Research Foundation (RRID:SCR\_005106)

---

### Resource Information

**URL:** <http://www.damonrunyon.org/>

**Proper Citation:** Damon Runyon Cancer Research Foundation (RRID:SCR\_005106)

**Description:** The Damon Runyon Cancer Research Foundation funds early career cancer researchers who have the energy, drive and creativity to become leading innovators in their fields. We identify the best young scientists in the nation and support them through four award programs: our Fellowship, Pediatric Cancer Fellowship, Clinical Investigator and Innovation Awards. Damon Runyon awards give young scientists: \* Freedom to follow their own ideas, explore new paths and take risks \* A prestigious endorsement that attracts further funding, advances their careers and accelerates their research \* Guaranteed financial support, sparing them hours applying for grants Since 1946, Damon Runyon has invested more than \$240 million in the best young minds in the nation. Our alumni include 11 Nobel Laureates and leaders of major cancer centers across the United States. Many of our 3,300 scientists have gone on to make breakthroughs in the way we prevent, diagnose and treat many forms of cancer. The Damon Runyon Cancer Research Foundation is a registered nonprofit with 501(c)(3) status.

**Abbreviations:** Damon Runyon Foundation

**Resource Type:** institution

**Keywords:** fellowship, grant, cancer

**Resource Name:** Damon Runyon Cancer Research Foundation

**Resource ID:** SCR\_005106

**Alternate IDs:** Crossref funder ID: 100001021, grid.453008.a, ISNI: 0000 0004 0508 2172, nlx\_144117

**Alternate URLs:** <https://ror.org/01gd7b947>

**Record Creation Time:** 20220129T080228+0000

**Record Last Update:** 20260801T190249+0000

---

## Ratings and Alerts

No rating or validation information has been found for Damon Runyon Cancer Research Foundation.

No alerts have been found for Damon Runyon Cancer Research Foundation.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 63 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#).

Schwoerer MP, et al. (2025) Receptor transporter protein 4 (RTP4)-mediated repression of hepatitis C virus replication in mouse cells. PLoS pathogens, 21(9), e1013412.

Nguyen E, et al. (2025) A small periplasmic protein governs broad physiological adaptations in Vibrio cholerae via regulation of the DbfRS two-component system. Nature communications, 16(1), 11230.

Pratyush MR, et al. (2025) Label-free microscopy enables high-throughput identification of genes controlling biofilm development. bioRxiv : the preprint server for biology.

Nguyen E, et al. (2025) A small periplasmic protein governs broad physiological adaptations in Vibrio cholerae via regulation of the DbfRS two-component system. bioRxiv : the preprint server for biology.

Roberge N, et al. (2025) Twitching motility suppressors reveal a role for FimX in type IV pilus extension dynamics. PLoS genetics, 21(10), e1011802.

Prentice JA, et al. (2024) Biofilm dispersal patterns revealed using far-red fluorogenic probes. PLoS biology, 22(11), e3002928.

Greaney AJ, et al. (2022) The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. bioRxiv : the preprint server for biology.

Greaney AJ, et al. (2022) A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. PLoS pathogens, 18(2), e1010248.

Greaney AJ, et al. (2022) The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. PLoS pathogens, 18(6), e1010592.

van Duinen AJ, et al. (2021) Catastrophic expenditure and impoverishment after caesarean section in Sierra Leone: An evaluation of the free health care initiative. *PloS one*, 16(10), e0258532.

Ehrenberg AJ, et al. (2021) Launching a saliva-based SARS-CoV-2 surveillance testing program on a university campus. *PloS one*, 16(5), e0251296.

Zinshteyn B, et al. (2021) Translational repression of NMD targets by GIGYF2 and EIF4E2. *PLoS genetics*, 17(10), e1009813.

Chang CH, et al. (2019) Islands of retroelements are major components of *Drosophila* centromeres. *PLoS biology*, 17(5), e3000241.

Muller M, et al. (2017) Nuclease escape elements protect messenger RNA against cleavage by multiple viral endonucleases. *PLoS pathogens*, 13(8), e1006593.

Park HB, et al. (2016) Pyrazinone protease inhibitor metabolites from *Photobacterium luminescens*. *The Journal of antibiotics*, 69(8), 616.

Iwasaki S, et al. (2016) Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor. *Nature*, 534(7608), 558.

Smith B, et al. (2016) Addiction to Coupling of the Warburg Effect with Glutamine Catabolism in Cancer Cells. *Cell reports*, 17(3), 821.

SoRelle ED, et al. (2016) A hyperspectral method to assay the microphysiological fates of nanomaterials in histological samples. *eLife*, 5.

Park HB, et al. (2016) Activating and Attenuating the Amicoumacin Antibiotics. *Molecules (Basel, Switzerland)*, 21(7).

Pacold ME, et al. (2016) A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. *Nature chemical biology*, 12(6), 452.